Thank you, Mr. Chair.
Great topic today, and thank you for your presentations.
I don't pretend to be an expert, certainly, on the science or medicine side of things, so I tried to follow along as best I could.
Ms. Szkotnicki, the presentation you handed out here today is quite illuminating. I just want to go over a couple of things so the committee understands. There have been a lot of comments made that I think might lead our viewers to be considerably alarmed, and perhaps not for the right reasons.
You made a distinction between the types of antibiotics in use in the veterinary realm. Mr. Dungate and some of the representatives of industry made reference to those used for therapeutic treatment. Are those the types used when bacterial infections require this kind of intervention? Is it this type of antibiotic use that might pose a potential risk to human antimicrobial resistance?
We've heard here today that the use of the therapeutic type, the stronger type, is limited. Yet we've heard, and there seems to be evidence, that somehow this is increasing microbial resistance in humans. So I'm trying to isolate the source. You say here that none of these pose any kind of risk to human health, so I wonder if you could help us there.